Table 4.

Association of AD neuropathological burden and functional cognitive scores with local European or non-European APOE4 + ancestries using corresponding ancestries of APOE4− individuals as references.

(A) EUR APOE4 + local ancestry (n = 31)a		Model 1 (no AFR adjustment)		Model 2 (with AFR adjustment)
Outcomes	Pathology adjustments	β (95% CI)	p	β (95% CI)	p
BB	NA	0.52 (0.01; 1.03)	0.048	0.51 (−0.002; 1.03)	0.051
CERAD	NA	0.61 (0.28; 0.95)	<0.001	0.61 (0.27; 0.95)	<0.001
CDR-SOB	NA	1.22 (−0.49; 2.93)	0.16	1.29 (−0.41; 2.99)	0.14
	BB + CERAD	0.52 (−1.06; 2.10)	0.52	0.55 (−1.02; 2.13)	0.49
	BB	0.92 (−0.66; 2.50)	0.25	0.97 (−0.61; 2.54)	0.23
	CERAD	0.25 (−1.34; 1.83)	0.76	0.31 (−1.27; 1.89)	0.70
(B) Non-EUR APOE4 + local ancestry (n = 17)b		Model 1 (no AFR adjustment)		Model 2 (with AFR adjustment)
BB	NA	−0.21 (−1.08; 0.65)	0.62	−0.21 (−1.10; 0.67)	0.62
CERAD	NA	0.01 (−0.52; 0.70)	0.76	0.09 (−0.51; 0.69)	0.76
CDR-SOB	NA	0.39 (−2.78; 3,56)	0.80	0.39 (−2.82; 3.60)	0.81
	BB + CERAD	1.53 (−1.60; 4.66)	0.33	1.53 (−1.66; 4.72)	0.33
	BB	1.45 (−1.41; 4.32)	0.31	1.45 (−1.46; 4.37)	0.32
	CERAD	0.59 (−2.50; 3.67)	0.70	0.59 (−2.54; 3.73)	0.70

Model 1: Linear regression model adjusted for age, sex, education, and AD neuropathology when indicated.

Model 2: Linear regression model adjusted for age, sex, education, AD neuropathology when indicated, and AFR.

OBS. Only individuals homozygous for APOE local ancestry were included.

AFR African ancestry (continuous 10% increments), BB Braak & Braak, CERAD Consortium to Establish a Registry for Alzheimer’s disease, NA not applicable.

^aReference for (A): Individuals APOE4− (genotypes 22, 23, or 33) with local European ancestries (n = 138).

^bReference for (B): Individuals APOE4− (genotypes 22, 23 or 33) with local non-European ancestries (n = 24).